Growth delayed, margins bottoming; GenX execution critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Management reaffirmed GenX breakeven expectation and maintained order intake guidance (₹800Cr–₹1,000Cr FY27), but explicitly acknowledged 'inflection points delayed' vs. Nov 2024 ₹10K Cr by 2030 vision.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Praj is investing heavily in growth (GenX, CBG, data centers, bio-IBA) backed by strong order intake (₹7.15B/quarter, ₹44.6B backlog), but near-term execution is challenged. Q2 revenue growth of 0.9% YoY is disappointingly flat despite claimed ₹1B international pipeline and GenX scaling. Margins (6.2% OPM) are under pressure from GenX capex; breakeven claimed within 12 months but contingent on model-dependent revenue conversion. Key risk: if GenX delays or international orders stall further, margin recovery could slip another 1–2 quarters, threatening 2030 guidance.
₹849 Cr
Revenue · +0.9% YoY₹23.2 Cr
Reported PAT · +20.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Order intake sustained at ₹7.1B; confident in growth
OVERSTATEDQ2 intake ₹7.15B strong, but YoY revenue growth only 0.9% (₹849 Cr vs ₹841 Cr prior year); backlog ₹44.6 Cr with 63% domestic concentration
EBITDA margins bottomed out at 6.2%; recovery ahead as GenX revenues flow
PartialQ2 OPM 6.2%, NPM 2.7%; GenX capex still ongoing, revenue trickling only from Q3; margin recovery contingent on model-dependent GenX scaling
GenX facility approved by 18 customers; 4 framework agreements operational; orders trickling from next quarter
METMD confirmed orders starting Q3 onwards; revenue ramp-up requires 12+ month lead time for engineering & manufacturing cycles; H1 GenX OpEx ~₹45 Cr/quarter
CBG JV with BPCL attractive economics; board approval given; can execute 8–10 plants over 2–3 years
PartialJV in setup phase (2–3 months), projects shortlisted but not finalized; execution cycle 12+ months per plant; policy-dependent on GoBarDhan incentives and feedstock availability
International markets (₹1000 Cr pipeline) developing in USA, Brazil, Argentina; expect conversion Q2–Q4
PartialPipeline cited; projects experiencing funding delays and customer challenges in prior calls; 38% of Q2 revenue from exports but international order intake only 38% of ₹7.15B (~₹2.7B)
Earnings quality
What changed since the last call
GenX breakeven visibility
DowngradeInitially guided as late FY27; now anchored to 'within 12 months from Q2' (Q3–Q4), requiring order-to-revenue conversion; prior call did not quantify, but implicit was earlier in year.
CBG commercialization timeline
NewBoard approval just granted this call; 2–3 month setup phase, then 12+ month first project execution cycle. Initial guidance was vague; now concrete but multi-step.
International order pipeline
MaintainedStill cited at ~₹1,000 Cr across USA, Brazil, Argentina, Southeast Asia; no change in quantum, but continued delays acknowledged (project funding challenges).
₹10K Cr by 2030 vision
DowngradeManagement confirmed pursuing same vision but explicitly stated 'inflection points delayed' (not cancelled); new growth levers (GenX data centers, CBG, Bio-IBA) to reach target via different path; original guidance path slipped.
The Q&A
Analysts pressed hard on margin recovery timeline, GenX capex payback, and CBG execution risks. Management was candid on numbers (₹45 Cr OpEx, ₹500–600 Cr breakeven revenue) but evasive on specific customer details (NDA) and data center order quantum. Q&A tone firm but defensive—management acknowledged delays without backing down on long-term vision.
Order intake sustainability — Atul Tiwari, JPMorgan
AnsweredThree growth areas developing: CBG, international markets, GenX. GenX facility approved by 18 customers; 4 framework agreements operational. Orders starting Q3 onwards. Opportunity pipeline in second half of FY27.
Margin trajectory — Atul Tiwari, JPMorgan
PartialEBITDA margins currently bottomed at 6.2%; GenX revenue inflow will improve margins going forward. Focused on delivery execution and margin improvement.
CBG JV economics — Amit Anwani, PL Capital
PartialBPCL biorefinery built with JV partnerships. Praj has proven CBG technology and deep customer knowledge. BPCL partnership enables market distribution. Value addition shared between partners.
Data center precision fabrication — Amit Anwani, PL Capital
DodgedExisting customer commitment is significant; engaging with multiple other customers for similar requirements. Scope for TAM expansion as more jobs added.
GenX fixed expense run-rate — Amit Anwani, PL Capital
AnsweredOperating expenses ₹25–30 Cr/quarter excluding interest and depreciation; total including interest and depreciation ~₹44–45 Cr/quarter.
GenX order guidance update — Shailesh Kanani, Asian Markets Securities
AnsweredWill maintain order booking within that range. Revenue conversion has certain cycles. Effects for GenX in Q3 and Q4. Remain within indicated range.
GenX PBT breakeven timeline — Manish Goyal, Thinqwise Wealth Managers
AnsweredWithin next 12 months, based on order inflow happening, will reach breakeven. Order inflows giving confidence for this timeline.
GenX CAPEX and shed activation — Manish Goyal, Thinqwise Wealth Managers
Answered7 sheds total; 2 equipped with plant/machinery. Incremental sheet activation requires minimal CAPEX—mainly equipment. Depreciation is on 10-year lease.
CBG JV structure — Ketan R. Chheda, individual investor
Answered50/50 with BPCL. OMCs putting up multiple plants across JVs. Revenue model has two legs—direct Praj execution revenue + JV-level gas sales. Contract revenue in EPC phase.
CBG JV ROI and timeline — Bharat Sheth, Quest Investment Managers
AnsweredExpecting 8–10 plants over 2–3 years minimum. Execution cycle for one project 12+ months. First plant commercial after 15 months setup. Attractive ROI under current GoBarDhan policy even without bio-manure revenue.
CBG differentiation — P. Jha, individual investor
AnsweredFinite capacity for JV projects; OMCs want multiple ventures. BPCL may want 50 plants across multiple JVs. Praj envisioning 8–10 in this JV. Technology credibility and multi-feedstock flexibility are differentiators.
₹10K Cr by 2030 vision progress — Pratyush Shah, individual investor
PartialStill pursuing same vision; some inflection points delayed but not cancelled. GenX (data centers), international markets, CBG, Bio-IBA as new growth levers to reach similar goals. Direction and ambition unchanged.
Guidance
GenX to achieve ₹500–600 Cr revenue (FY27–FY28 cumulative)
MediumDependent on order-to-revenue conversion cycles (12+ months engineering, manufacturing, delivery). Breakeven EBITDA targeted within 12 months from Q2 (Q3–Q4 FY27 visibility).
Order intake maintained ₹800Cr–₹1,000Cr FY27 (vs ₹7.15B Q2 run-rate)
HighFour quarters of similar intake expected; strong bioenergy demand, international pipeline ₹1,000 Cr, GenX orders beginning. Maintained prior guidance.
International orders ₹1,000 Cr pipeline over next few quarters (Q2–Q4 FY27)
LowProject funding delays cited; customer funding challenges ongoing. Timeframe stretched; conversion to revenue lagging.
EBITDA margins to improve from 6.2% as GenX revenues start trickling in
MediumGenX OpEx ₹45 Cr/quarter; EBITDA breakeven at ₹150 Cr+ quarterly revenue from GenX. Leverage to come from scaling beyond breakeven.
Target high single-digit margins (8–9%) over next 2–3 years
LowImplicit; dependent on GenX scale, CBG commercialization, and improved order mix. No explicit guidance provided; hedged with 'will see'.
GenX capex structure: 7 sheds ready; incremental capex for new shed activation minimal
HighExisting facilities substantially built; new shed activation requires equipment only, not major civil. 10-year facility lease post 3-year free period.
CBG JV capex ₹100 Cr equity from Praj side (no timeline specific)
MediumBoard approval granted; 2–3 month setup phase; 8–10 plants envisioned; phased capex deployment over 2–3 years.
Risks the call surfaced
GenX execution & capex recovery
HighGenX facility operational but revenue trickling only from Q3 FY27. Breakeven dependent on achieving ₹500–600 Cr revenue within 12 months; if delayed, capex drag extends, margin recovery pushed to FY28.
International order conversion delays
Medium₹1,000 Cr international pipeline cited over 'next few quarters,' but projects facing funding delays (acknowledged by management in prior calls). 38% of Q2 order intake from international; conversion to revenue stalling.
CBG JV execution risk
HighCBG JV board-approved but in setup phase (2–3 months). First plant execution 12+ months away; commercialization 15+ months away. Market unproven at scale; dependent on GoBarDhan policy incentives and feedstock availability.
Ethanol blending mandate policy risk
Medium69% of export revenue from bioenergy (ethanol, CBG); dependent on E100 blending mandates and government policy. E100 legalization only recently announced (Oct 2026); adoption uncertain.
Order backlog concentration
Medium₹44.6 Cr backlog 63% domestic; likely concentrated among a few large customers in bioenergy/oil & gas. Loss of single large order could impact 1–2 quarters of revenue.
Management
Score 6/10. Clear on numbers (GenX OpEx ₹45 Cr/quarter, breakeven ₹500–600 Cr revenue). Evasive on specifics (data center order value withheld due to NDA; CBG project timelines vague). Candid on delays acknowledged vs. prior vision. GenX approvals from 18 customers and 4 framework agreements operational—credible. BioCBG: 5,000 tons produced in 500 days—proven. But international project funding delays persistent. On-time delivery track record not discussed.
1 · Q3 FY27
GenX orders begin trickling to revenue; margin ramp initiation
2 · Q1 FY28
GenX targeting EBITDA breakeven (within 12 months); expected revenue ₹500–600 Cr cumulative
3 · Q4 FY27
CBG JV operationalized; first project execution begins (12+ month lead to commercial production)
Key risk: if GenX delays or international orders stall further, margin recovery could slip another 1–2 quarters, threatening 2030 guidance.
Informational and educational content only. Not investment advice.